143 related articles for article (PubMed ID: 16598555)
1. [The importance of cholesterol-lowering in patients after coronary artery bypass surgery].
von Hodenberg E; Breidenbach T; Melichercik J
Clin Res Cardiol; 2006 Jan; 95 Suppl 1():i78-82. PubMed ID: 16598555
[TBL] [Abstract][Full Text] [Related]
2. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
Post Coronary Artery Bypass Graft Trial Investigators
N Engl J Med; 1997 Jan; 336(3):153-62. PubMed ID: 8992351
[TBL] [Abstract][Full Text] [Related]
3. The benefit of cholesterol-lowering medications after coronary revascularization: a population study.
Brophy JM; Brassard P; Bourgault C
Am Heart J; 2005 Aug; 150(2):282-6. PubMed ID: 16086931
[TBL] [Abstract][Full Text] [Related]
4. Coronary artery bypass grafting in familial hypercholesterolemia.
Kawasuji M; Sakakibara N; Takemura H; Matsumoto Y; Mabuchi H; Watanabe Y
J Thorac Cardiovasc Surg; 1995 Feb; 109(2):364-9. PubMed ID: 7853888
[TBL] [Abstract][Full Text] [Related]
5. Prevention of atherosclerosis in coronary-artery bypass grafts.
Fuster V; Vorchheimer DA
N Engl J Med; 1997 Jan; 336(3):212-3. PubMed ID: 8988902
[No Abstract] [Full Text] [Related]
6. What is new in the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic risk in adults?
Virani SS
Tex Heart Inst J; 2014 Jun; 41(3):304-5. PubMed ID: 24955047
[No Abstract] [Full Text] [Related]
7. Lipid-lowering therapy after coronary artery bypass surgery: the Post-CABG trial.
Stewart WJ; Hoogwerf BJ
Cleve Clin J Med; 1997; 64(7):347-51. PubMed ID: 9223762
[TBL] [Abstract][Full Text] [Related]
8. Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study.
Tomasik T; Jozwiak J; Windak A; Rygiel K; Mastej M; Smithson WH; Mathers N; Tomaszewski M; Kaess BM; Tykarski A; Konduracka E; Grzeszczak W; Lukas W
Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):287-96. PubMed ID: 21450675
[TBL] [Abstract][Full Text] [Related]
9. Hypercholesterolemia in youth: opportunities and obstacles to prevent premature atherosclerotic cardiovascular disease.
McNeal CJ; Dajani T; Wilson D; Cassidy-Bushrow AE; Dickerson JB; Ory M
Curr Atheroscler Rep; 2010 Jan; 12(1):20-8. PubMed ID: 20425267
[TBL] [Abstract][Full Text] [Related]
10. Achieving optimal lipid goals in patients with coronary artery disease.
Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
[TBL] [Abstract][Full Text] [Related]
11. The evolution of European guidelines: changing the management of cholesterol levels.
Erhardt LR; Gotto A
Atherosclerosis; 2006 Mar; 185(1):12-20. PubMed ID: 16309687
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol treatment and changes in guidelines in an academic medical practice.
Schoen MW; Salas J; Scherrer JF; Buckhold FR
Am J Med; 2015 Apr; 128(4):403-9. PubMed ID: 25460526
[TBL] [Abstract][Full Text] [Related]
13. The impact of lipid lowering in coronary artery disease.
Goldberg AC
Curr Opin Cardiol; 1997 Sep; 12(5):488-93. PubMed ID: 9352177
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol-lowering and coronary atherosclerosis: good news and bad news.
Kreisberg RA
Am J Med; 1996 Nov; 101(5):455-8. PubMed ID: 8948266
[No Abstract] [Full Text] [Related]
15. [Prevalence and treatment of hypercholesterolemia in patients with manifest vascular disease according to practice guidelines of the current cholesterol consensus].
van de Laak MF; van der Graaf Y; Banga JD; Simons PC; Algra A
Ned Tijdschr Geneeskd; 2000 Apr; 144(15):706-9. PubMed ID: 10778719
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal.
Windler E; Zyriax BC
Atheroscler Suppl; 2015 May; 18():176-9. PubMed ID: 25936323
[TBL] [Abstract][Full Text] [Related]
17. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Shah SJ; Waters DD; Barter P; Kastelein JJ; Shepherd J; Wenger NK; DeMicco DA; Breazna A; LaRosa JC
J Am Coll Cardiol; 2008 May; 51(20):1938-43. PubMed ID: 18482661
[TBL] [Abstract][Full Text] [Related]
18. [An updated overview of the high intensity lipid lowering therapy in high cardiovascular risk patients].
Pedro-Botet J; Pintó X
Clin Investig Arterioscler; 2016; 28(1):19-30. PubMed ID: 26657098
[TBL] [Abstract][Full Text] [Related]
19. [Lipid lowering after percutaneous coronary intervention. Intended and achieved treatment goals in real life].
Germing A; Lindstaedt M; Mügge A
Med Klin (Munich); 2005 Dec; 100(12):781-4. PubMed ID: 16453092
[TBL] [Abstract][Full Text] [Related]
20. IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
Masana L; Pedro-Botet J; Civeira F
Atherosclerosis; 2015 May; 240(1):161-2. PubMed ID: 25795557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
